CohBar, Inc. Announces First Quarter 2015 Financial Results
Business Wire - Fri May 15, 7:30AM CDT
CohBar, Inc. (TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics to treat diseases associated with aging, today reported financial results for the three months ended March 31, 2015.
COB-U.VN: 0.960 (+0.060)
CohBar, Inc. Announces Full Year 2014 Financial Results
Business Wire - Tue Mar 31, 8:00AM CDT
CohBar, Inc. (TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics to treat diseases associated with aging, today provided a corporate update and reported financial results for the full year ending December 31, 2014.
COB-U.VN: 0.960 (+0.060)
KILL CohBar, Inc. Announces Publication of Preclinical Proof-of-Principle of MOTS-c and its Role in Metabolic Regulation
Business Wire - Mon Mar 02, 5:45PM CST
CohBar requests that their press release NewsItemId: 20150302005162 issued on March 2, 2015 entitled "CohBar, Inc. Announces Publication of Preclinical Proof-of-Principle of MOTS-c and its Role in Metabolic Regulation" be killed.
CohBar, Inc. Announces Publication of Preclinical Proof-of-Principle of MOTS-c and its Role in Metabolic Regulation
Business Wire - Mon Mar 02, 11:00AM CST
CohBar, Inc. (TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics to treat diseases associated with aging, today announced that researchers have discovered MOTS-c, a new mitochondrial-derived peptide hormone that prevents obesity caused by a high-fat diet and stimulates the metabolism in the same way as exercise. The research, "The Mitochondrial-Derived Peptide, MOTS-c, Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance," appears online and in the March 3, 2015 issue of Cell Metabolism. CohBar has an exclusive, worldwide license for the development of MOTS-c into therapeutics.
COB-U.VN: 0.960 (+0.060)